Pentoxifylline reverses oxidative mitochondrial defect in claudicating skeletal muscle

Journal of Surgical Research

Volumn 102, Issue 2, 2002, Pages 126-132

  Pipinos, Iraklis I ^a   Boska, Michael D ^a   Shepard, Alexander D ^b   Anagnostopoulos, Petros V ^b   Katsamouris, Asterios ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CREATINE PHOSPHATE; PENTOXIFYLLINE;

ADULT; AGED; ARTICLE; BIOENERGY; CLAUDICATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; GASTROCNEMIUS MUSCLE; HUMAN; MALE; MUSCLE MITOCHONDRION; OXIDATIVE STRESS; PHYSICAL CAPACITY; PRIORITY JOURNAL; SKELETAL MUSCLE; TREADMILL; TREATMENT OUTCOME; WALKING;

EID: 0036353399     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.2001.6292     Document Type: Article

References (18)

1. Value of arterial pressure measurements in the proximal and distal part of the thigh in arterial occlusive disease
2. Abnormal muscle mitochondria in ischemic claudication
3. Skeletal muscle mitochondrial DNA injury in patients with unilateral peripheral arterial disease
4. Muscle enzyme adaptation in patients with peripheral arterial insufficiency: Spontaneous adaptation, effect of different treatments and consequences on walking performance
5. Phosphorus magnetic resonance spectroscopy (31P MRS) in neuromuscular disorders
6. Skeletal muscle metabolism as a target for drug therapy in peripheral arterial disease
7. 31P nuclear magnetic resonance spectroscopy suggests mitochondrial defect in claudicating skeletal muscle
8. 31P MRS studies of exercising human muscle at high temporal resolution
9. 31P nuclear magnetic resonance spectroscopy: Non-invasive biochemical analysis of the ischemic extremity
10. 31P magnetic resonance spectroscopy of abnormal mitochondrial oxidation in skeletal muscle during recovery from exercise
11. Management of intermittent claudication with pentoxifylline: Meta-analysis of randomized controlled trials
12. Pentoxifylline for intermittent claudication. A critical review
13. Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication
14. Conservative management of intermittent claudication
15. 31P MRS
16. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline
17. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway
18. Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study